Corporate structure, indirect bankruptcy costs, and the advantage of de novo firms: The case of gene therapy research

Organization Science

Volumn 25, Issue 3, 2014, Pages 850-867

  Sosa, M Lourdes ^a  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

Bankruptcy costs; Biotechnology; Corporate structure; Discontinuities; Gene therapy; Incumbents; R d; Technological change

Indexed keywords

EID: 84901304221     PISSN: 10477039     EISSN: 15265455     Source Type: Journal    
DOI: 10.1287/orsc.2013.0876     Document Type: Article

References (71)

1. Abernathy WJ, Utterback JM (1978) Patterns of industrial innovation. Tech. Rev. 80(7):40-47.
2. Adner R, Levinthal DA (2004a) What is not a real option: Considering boundaries for the application of real options to business strategy. Acad. Management Rev. 29(1):74-85.
3. Adner R, Levinthal DA (2004b) Real options and real tradeoffs. Acad. Management Rev. 29(1):120-126.
4. American Cancer Society (2000) Cancer facts and figures. Report, American Cancer Society, Washington, DC. http://www.cancer .org/downloads/STT/F&F00.pdf. [Last accessed March 10, 2008 (site discontinued).]
5. American Cancer Society (2004) Cancer facts and figures. Report, American Cancer Society, Washington, DC. http://www.cancer .org/downloads/STT/CAFF_finalPWSecured.pdf.[Last accessed March 25, 2009 (site discontinued).]
6. Arora A, Fosfuri A, Gambardella A (2004) Markets for Technology: The Economics of Innovation and Corporate Strategy (MIT Press, Cambridge, MA)
7. Bechky BA (2006) Gaffers, gofers, and grips: Role-based coordination in temporary organizations. Organ. Sci. 17(1):3-21.
8. Benner MJ (2010) Securities analysts and incumbent response. Organ. Sci. 21(1):42-62.
9. Benner MJ, Tripsas M (2012) The influence of prior industry affiliation on framing in nascent industries: The evolution of digital cameras. Strategic Management J. 33(3):277-302.
10. Brealey RA, Myers SC, Allen F (2010) Principles of Corporate Finance, 10th ed. (McGraw-Hill, New York).
11. Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imanitib), a rationally developed, targeted anticancer drug. Nature Rev. Drug Discovery 1(7):493-502.
12. Carroll GR, Bigelow LS, Seidel M-DL, Tsai LB (1996) The fates of de novo and de alio producers in the American automobile industry 1885-1981. Strategic Management J. 17(S1):117-137.
13. Chabner BA, Roberts TG Jr(2005) Chemotherapy and the war on cancer. Nature Rev. Cancer 5(1):65-72.
14. Christensen C, Bower J (1996) Customer power, strategic investment, and the failure of leading firms. Strategic Management J. 17(3):197-218.
15. Clark KB (1985) The interaction of design hierarchies and market concepts in technological innovation. Res. Policy 14(5):235-251.
16. Cohen LE (2012) Assembling jobs: A model of how tasks are bundled into and across jobs. Organ. Sci. 24(2):432-454.
17. Cohen WM, Levinthal DA (1990) Absorptive capacity-A new perspective on learning and innovation. Admin. Sci. Quart. 35(1): 128-152.
18. Cotrim AP, Baum BJ (2008) Gene therapy: Some history, applications, problems and prospects. Toxicol. Pathol. 36(1):97-103.
19. Datamonitor (2011) MolMed to develop production process for ADASCID gene therapy. Press release (August 10), MolMed, Milan, Italy.
20. 2012 First broadcast March 4 by NBC News. Dateline NBC Episode 1927 (Profile: The Hansen files- Investigation into how drugs get approved). Transcript retrieved from Factiva, September 11, 2012.
21. Edelstein ML, Abedi MR, Wixon J (2007) Gene therapy clinical trials worldwide to 2007-An update. J. Gene Medicine 9(10):833-842.
22. Edelstein ML, Abedi MR, Wixon J, Edelstein RM (2004) Gene therapy clinical trials worldwide 1989-2004-An overview. J. Gene Medicine 6(6):597-602.
23. Feldman M (2003) The locational dynamics of the US biotech industry: Knowledge externalities and the anchor hypothesis. Indust. Innovation 10(3):311-329.
24. Fernández-Mateo I (2009) Cumulative gender disadvantage in contract employment. Amer. J. Sociol. 114(4):871-923.
25. Ferrera N, Hillan KJ, Gerber H, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Rev. Drug Discovery 3(5):391-400.
26. Financial Times (1995) Weekend money (company in the news)- Boot's 600 M poser. Financial Times (June 3). Retrieved from Factiva, August 29, 2012.
27. Friedmann T (1992) A brief history of gene therapy. Nature Genetics 2(2):93-98.
28. Gans JS, Stern S (2003) The product market and the market for "ideas": Commercialization strategies for technology entrepreneurs. Res. Policy 32(2):333-350.
29. Glaser BG, Strauss AL (1967) The Discovery of Grounded Theory (Aldine Publishing, Hawthorne, NY)
30. Guedj I, Scharfstein D (2004) Organizational scope and investment: Evidence from the drug development strategies and performance of biopharmaceutical firms. NBER Working Paper 10933, National Bureau of Economic Research, Cambridge, MA.
31. Henderson RM (1993) Underinvestment and incompetence as responses to radical innovation-Evidence from the photolithographic alignment equipment industry. RAND J. Econom. 24: 248-270.
32. Holmstrom B (1989) Agency costs and innovation. J. Econom. Behav. Organ. 12(3):305-327.
33. Huising R (2012) Becoming a workplace activist. Working paper, McGill University, Montreal.
34. Jia H (2006) Controversial Chinese gene-therapy drug entering unfamiliar territory. Nature Rev. Drug Discovery 5(4):269-270.
35. Jia H (2007) Gene dreams troubled by market realities. Chemistry World (August 31) http://www.rsc.org/chemistryworld/Issues/ 2007/September/GeneDreamsTroubledMarketRealities.asp.
36. Kaplan S (2008) Cognition, capabilities, and incentives: Assessing firm response to the fiber-optic revolution. Acad. Management J. 51(4):672-695.
37. Kaplan S, Murray F (2010) Entrepreneurship and the construction of value in biotechnology. Research in the Sociology of Organizations. Phillips N, Griffiths D, Sewell G, eds. Technology and Organization: Essays in Honour of Joan Woodward, (Emerald Group Publishing, Bingley, UK), 29, 107-147.
38. Kaplan S, Tripsas M (2008) Thinking about technology: Applying a cognitive lens to technical change. Res. Policy 37(5):790-805.
39. Kaplan S, Murray F, Henderson RM (2003) Discontinuities and senior management: Assessing the role of recognition in pharmaceutical firm response to biotechnology. Indust. Corporate Change 12(4):203-233.
40. Kellogg KC (2009) Operating room: Relational spaces and microinstitutional change in surgery. Amer. J. Sociol. 115(3):657-711.
41. Kimmelman J (2009) Ethics of cancer gene transfer clinical research. Walther W, Stein US, eds. Methods in Molecular Biology, Gene Therapy of Cancer, Vol. 542 (Humana Press, Totowa, NJ), 423-445.
42. Klepper S, Thompson P (2006) Submarkets and the evolution of market structure. RAND J. Econom. 37(4):861-886.
43. Kohn DB, Candotti F (2009) Gene therapy fulfilling its promise. New England J. Medicine 360(5):518-521.
44. Loftus P (2007) Tales of the tape: Investors mull safety of Arena's diet pill. Dow Jones News (June 12). Retreived from Factiva, August 29, 2012.
45. McGrath RG (1997) A real options logic for initiating technology positioning investments. Acad. Management Rev. 22(4): 974-996.
46. McGrath RG, Nerkar A (2004) Real options reasoning and a new look at the R&D investment strategies of pharmaceutical firms. Strategic Management J. 25(1):1-21.
47. McGrath RG, Ferrier WJ, Mendelow AL (2004) Real options as engines of choice and heterogeneity. Acad. Management Rev. 29(1):86-101.
48. ®. Press release (September 30), Merck & Co., North Wales, PA. http://www.pbm.va.gov/vacenterformedicationsafety/vioxx/DearHealthcareProfessional.pdf.
49. Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsödi J, Boll W, Cantell K, Weissmann C (1980) Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 284(5754):316-320.
50. Nature (2007) Nature milestones in DNA technologies: PDF of all milestones. Nature (October, supplement):S5-S20.
51. Panem S(1984) The Interferon Crusade (Brookings Institution, Washington, DC)
52. Parsons SJ, Parsons JT (1987) Monoclonal antibodies to oncogene products. Schook LB, ed. Monoclonal Antibody Production Techniques and Applications (Marcel Dekker, New York), 207-228.
53. Rang HP (2006) The drug discovery process: General principles and some case histories. Rang HP, ed. Drug Discovery and Development: Technology in Transition (Churchill Livingstone, London), 43-56.
54. Reuters (2006) Merck sees slightly higher 2007 earnings. New York Times (December 7) http://www.nytimes.com/2006/12/07/business/07drug.html.
55. Roberts TG Jr, Goulat BH, Squitieri L, Stallings SC, Halpern EF, Chabner BA, Gazelle GS, Finkelstein SN, Clark JW (2004) Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. J. Amer. Medical Assoc. 292(17): 2130-2140.
56. Ryser S, Weber M (1990) Genetic Engineering-A Chronology, 2nd rev. ed. (Editiones Roche, Basel, Switzerland).
57. Sleigh S, Barton CL (2011) Risk evaluation and mitigation strategies (REMS): Detecting risk pre-market, managing risk postapproval, and the role of US and EU regulators. Report, Business Insights, London. http://www.popewoodhead.com/downloads/SCRIP_REMS_Aug11.pdf.
58. Sosa ML (2011) From old competence destruction to new competence access: Evidence from the comparison of two discontinuities in anticancer drug discovery. Organ. Sci. 22(6):1500-1516.
59. Stuart TE, Hoang H, Hybels RC (1999) Interorganizational endorsements and the performance of entrepreneurial ventures. Admin. Sci. Quart. 44(2):315-349.
60. Sutton J (1998) Technology and Market Structure: Theory and Structure (MIT Press, Cambridge, MA)
61. Teece DJ, Pisano G, Schuen A (1997) Dynamic capabilities and strategic management. Strategic Management J. 18(7):509-533.
62. Thompson L (2000) Human gene therapy: Harsh lessons, high hopes. FDA Consumer 34(5):19-24.
63. Tilton JE (1971) International Diffusion of Technology: The Case of Semiconductors (Brookings Institution, Washington, DC)
64. Tripsas M (1997) Unraveling the process of creative destruction: Complementary assets and incumbent survival in the typesetter industry. Strategic Management J. 18(Summer special issue): 119-142.
65. Tripsas M (2008) Customer preference discontinuities: A trigger for radical technological change. Managerial Decision Econom. 29:79-97.
66. Tripsas M (2009) Technology, identity, and inertia through the lens of "The Digital Photography Company." Organ. Sci. 20(2):441-460.
67. Tripsas M, Gavetti G (2000) Capabilities, cognition, and inertia: Evidence from digital imaging. Strategic Management J. 21(10-11):1147-1161.
68. Tushman M, Anderson P (1986) Technological discontinuities and organizational environments. Admin. Sci. Quart. 31(3):439-465.
69. Tyle P, Ram BP (1990) Monoclonal antibodies, immunoconjugates and liposomes as targeted therapeutic systems. Tyle P, Ram BP, eds. Targeted Therapeutic Systems (CDC Press, Boca Raton, FL), 3-24.
70. Vassolo RS, Anand J, Folta TB (2004) Non-additivity in portfolios of exploration activities. Strategic Management J. 25(11): 1045-1061.
71. Ziedonis AA (2007) Real options in technology licensing. Management Sci. 53(10):1618-1633.